Chicago—Maintenance lenalidomide extends the overall survival (OS) of patients with multiple myeloma by about 2.5 years after autologous hematopoietic cell transplant (auto-HCT), according to a meta-analysis of published Phase III multicenter trials.
Although this treatment, compared with placebo or no treatment, was associated with a significantly increased risk for secondary primary hematologic malignancies and solid tumors, the investigators concluded that the benefit outweighs the